Shots:
- BeiGene and Asieris collaborate to evaluate the safety and efficacy of APL-1202 + tislelizumab as neoadjuvant therapy in patients with MIBC. APL-1202 has been approved to treat patients with locally advanced or metastatic UC and high expression of PD-L1 who failed to receive platinum-based CT
- Asieris plans to submit INDs in China and the US for P- I/II clinical study and determine the RP2D (recommended P-II dose)
- APL-1202 is an orally reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities, currently in P- III clinical trials in China as monthx for the 1L treatment of non-muscle invasive for the 2L treatment of NMIBC
Click here to read full press release/ article | Ref: PRNewswire | Image: BeiGene
The post BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer first appeared on PharmaShots.
